Flexion Therapeutics CEO Michael Clayman's 2018 pay jumps 200% to $3.2M
Flexion Therapeutics reports 2018 executive compensation
By ExecPay News
Published: April 26, 2019
Flexion Therapeutics reported fiscal year 2018 executive compensation information on April 26, 2019.
In 2018, five executives at Flexion Therapeutics received on average a compensation package of $2.1M, a 12% increase compared to previous year.
Average pay of disclosed executives at Flexion Therapeutics
Michael D. Clayman, Chief Executive Officer, received $3.2M in total, which increased by 200% compared to 2017. 52% of Clayman's compensation, or $1.7M, was in option awards. Clayman also received $252K in bonus, $600K in salary, $651K in stock awards, as well as $31K in other compensation.
David Arkowitz, Chief Financial Officer, received a compensation package of $3.2M. 62% of the compensation package, or $2M, was in option awards.
Neil Bodick, Chief Scientific Officer, earned $1.4M in 2018, a 100% increase compared to previous year.
Mark S. Levine, General Counsel, received $1.2M in 2018, which decreases by 42% compared to 2017.
Scott Kelly, Chief Medical Officer, earned $1.2M in 2018.
Related executives
You may also like
Source: SEC filing on April 26, 2019.